Summary: Harmony Biosciences Holdings Inc described initially-quarter effects, showcasing development in its rest/wake portfolio. Key highlights consist of a rise in sufferers on Wakix, enhancements in the idiopathic hypersomnia program with designs for pitolisant, and positive … [Read more...]